Disease Modifying Therapy Archives

Novartis data at AAN show Gilenya is only disease-modifying therapy with proven superiority versus glatiramer acetate in RRMS

Clinical Data, Clinical Studies, Clinical Trials, Disease Modifying Therapy, R&D, Relapsing-Remitting Multiple Sclerosis

Novartis announced the full data of the ASSESS study, which evaluated the efficacy of oral, once-daily Gilenya (fingolimod) at 0.5mg and 0.25mg versus once-daily subcutaneous injections of glatiramer acetate 20mg in reducing disease activity over 12 months in patients with relapsing remitting multiple sclerosis (RRMS).

May 10, 2019/by Administrator

Novartis’ Siponimod accepted for FDA review

Clinical Trials, Disease Modifying Therapy, FDA, FDA/Regulatory, Filing Acceptance, Filing Acceptance, Secondary Progressive Multiple Sclerosis (SPMS)

The U.S. FDA accepted Novartis’ New Drug Application for the investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.

October 8, 2018/by PR Newswire